Genomma Lab Internacional S.A.B. de C.V (MX:LABB) — Market Cap & Net Worth
Market Cap & Net Worth: Genomma Lab Internacional S.A.B. de C.V (LABB)
Genomma Lab Internacional S.A.B. de C.V (MX:LABB) has a market capitalization of $846.86 Million (MX$14.72 Billion) as of June 22, 2026. Listed on the MX stock exchange, this Mexico-based company holds position #9795 globally and #90 in its home market, demonstrating a 1.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genomma Lab Internacional S.A.B. de C.V's stock price MX$15.05 by its total outstanding shares 977752666 (977.75 Million). Review Genomma Lab Internacional S.A.B. de C.V debt and liabilities to assess the company's total debt and financial obligations.
Genomma Lab Internacional S.A.B. de C.V Market Cap History: 2015 to 2026
Genomma Lab Internacional S.A.B. de C.V's market capitalization history from 2015 to 2026. Data shows growth from $676.40 Million to $846.86 Million (2.75% CAGR).
Genomma Lab Internacional S.A.B. de C.V Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genomma Lab Internacional S.A.B. de C.V's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.06x
Genomma Lab Internacional S.A.B. de C.V's market cap is 0.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.62x
Genomma Lab Internacional S.A.B. de C.V's market cap is 0.62 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.05 Billion | $11.32 Billion | -$1.68 Billion | 0.09x | N/A |
| 2017 | $1.00 Billion | $12.08 Billion | $1.28 Billion | 0.08x | 0.78x |
| 2018 | $569.94 Million | $11.79 Billion | $1.11 Billion | 0.05x | 0.51x |
| 2019 | $913.75 Million | $12.71 Billion | $764.46 Million | 0.07x | 1.20x |
| 2020 | $920.10 Million | $13.87 Billion | $1.47 Billion | 0.07x | 0.63x |
| 2021 | $1.07 Billion | $15.49 Billion | $1.31 Billion | 0.07x | 0.82x |
| 2022 | $883.92 Million | $16.82 Billion | $1.39 Billion | 0.05x | 0.64x |
| 2023 | $769.96 Million | $16.47 Billion | $1.03 Billion | 0.05x | 0.75x |
| 2024 | $1.43 Billion | $18.61 Billion | $1.49 Billion | 0.08x | 0.95x |
| 2025 | $1.01 Billion | $17.54 Billion | $1.61 Billion | 0.06x | 0.62x |
Competitor Companies of LABB by Market Capitalization
Companies near Genomma Lab Internacional S.A.B. de C.V in the global market cap rankings as of June 22, 2026.
Key companies related to Genomma Lab Internacional S.A.B. de C.V by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
Genomma Lab Internacional S.A.B. de C.V Historical Marketcap From 2015 to 2026
Between 2015 and today, Genomma Lab Internacional S.A.B. de C.V's market cap moved from $676.40 Million to $ 846.86 Million, with a yearly change of 2.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | MX$846.86 Million | -15.97% |
| 2025 | MX$1.01 Billion | -29.32% |
| 2024 | MX$1.43 Billion | +85.19% |
| 2023 | MX$769.96 Million | -12.89% |
| 2022 | MX$883.92 Million | -17.37% |
| 2021 | MX$1.07 Billion | +16.26% |
| 2020 | MX$920.10 Million | +0.70% |
| 2019 | MX$913.75 Million | +60.33% |
| 2018 | MX$569.94 Million | -43.13% |
| 2017 | MX$1.00 Billion | -4.65% |
| 2016 | MX$1.05 Billion | +55.38% |
| 2015 | MX$676.40 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Genomma Lab Internacional S.A.B. de C.V was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $846.86 Million USD |
| MoneyControl | $846.86 Million USD |
| MarketWatch | $846.86 Million USD |
| marketcap.company | $846.86 Million USD |
| Reuters | $846.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genomma Lab Internacional S.A.B. de C.V
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products t… Read more